2004 Annual Meeting | Management of Common Behavioral Disturbances in Dementia

Date Monday 04/26/04

Time 06:30 PM - 09:30 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Dinner Seminar

Director(s) Douglas W. Scharre, MD, FAAN

Topic(s) Aging/Dementia/Degenerative Disease

Learning Objectives Upon completion:
Participants should be able to identify target behavioral symptoms in dementia patients; apply nonpharmacologic behavioral modification interventions to their dementia patients; and utilize a rational approach to the pharmacological management of aggressiveness and other common behavioral disturbances.

CME Available No CME available

Program Level Advanced

Recommended Audience Practitioner, Fellow, Resident, Nurse

Event Timeline
06:30 PM - 07:25 PM		Introduction and Preferred Approaches for the Management of Affective Disturbances and Neurovegetative Dysfunctioning in Dementia Douglas W. Scharre, MD, FAAN
07:25 PM - 08:05 PM		Preferred Approaches for the Management of Aggression and Psychosis in Dementia David L. Sultzer, MD
08:05 PM - 08:35 PM		Behavioral Modification Approaches Douglas W. Scharre, MD, FAAN
08:35 PM - 09:15 PM		Case Studies
09:15 PM - 09:30 PM		Questions and Answers

Faculty Disclosures
Douglas W. Scharre, MD, FAAN	Dr. Scharre has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for BrainTest, Inc. Dr. Scharre has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Otsuka. Dr. Scharre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. Dr. Scharre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Scharre has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Eisai. Dr. Scharre has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Eli Lilly. The institution of Dr. Scharre has received research support from InSightec. The institution of Dr. Scharre has received research support from Alzheimer's Therapeutic Research Institute (ATRI). The institution of Dr. Scharre has received research support from Eisai. The institution of Dr. Scharre has received research support from vTv Therapeutics. The institution of Dr. Scharre has received research support from National Institute of Health. The institution of Dr. Scharre has received research support from Eli Lilly. The institution of Dr. Scharre has received research support from Biogen. The institution of Dr. Scharre has received research support from Roche. The institution of Dr. Scharre has received research support from Percision Medicine. The institution of Dr. Scharre has received research support from Premier Research Group. The institution of Dr. Scharre has received research support from Genetch. The institution of Dr. Scharre has received research support from Avanir. The institution of Dr. Scharre has received research support from Cerevel Therapeutics. The institution of Dr. Scharre has received research support from Janssen. The institution of Dr. Scharre has received research support from Cassava. The institution of Dr. Scharre has received research support from UniQure. The institution of Dr. Scharre has received research support from Cognition Therapeutics. The institution of Dr. Scharre has received research support from Cognitive Research Corporation. The institution of Dr. Scharre has received research support from EIP. The institution of Dr. Scharre has received research support from Cognito. Dr. Scharre has received intellectual property interests from a discovery or technology relating to health care. Dr. Scharre has received intellectual property interests from a discovery or technology relating to health care.
David L. Sultzer, MD	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��